Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.
Nephrology, Dialysis and Transplantation AOUP Pisa, Pisa, Italy.
Clin Exp Nephrol. 2019 Sep;23(9):1147-1153. doi: 10.1007/s10157-019-01759-w. Epub 2019 Jun 22.
Retroperitoneal fibrosis (RF) is a rare disease of unclear etiology characterized by the presence of fibroinflammatory tissue in the retroperitoneal space, which can entrap and obstruct retroperitoneal structures, notably the ureters. The disease responds well to steroid therapy, but tends to recur even after years. The aim of our study was to evaluate the long-term renal outcome of patients affected by idiopathic retroperitoneal fibrosis looking for predictive risk factors for recurrence of the disease and progression to end-stage renal disease.
Retrospective observational study of patients with idiopathic RF diagnosed from 2004 to 2017 and follow-up of at least 1 year after the end of first course therapy with steroid, with or without tamoxifen (TMX) and with urological procedures when applicable.
Forty-three patients were included in the study. The follow-up was 93 ± 52 months. All the patients obtained remission after therapy that was maintained until the last observation in 26 of them. In 17 patients, there was at least one recurrence. Risk factors associated with relapse were identified and resulted in smoking habit, onset with acute kidney injury (AKI), low back pain and antinuclear antibodies (ANA) positivity. Renal function remained fairly stable during the long-term follow-up. The renal end-point (doubling of serum creatinine or ESRD) occurred in 8% of the patients; however, eGFR in patients with relapse was similar to that of non-recurrent at the diagnoses, but it decreased over time more in the relapsing than in non-relapsing patients (p group = 0.20; p time = 0.001; p time × group interactions = 0.04). Based on these 4 predictor conditions, patients were divided into "low risk" (with 0-1 risk factor), and "high risk" (3-4 risk factors). The renal end-point occurred in 40% of high-risk patients, while none of the low-risk patients reached it (p = 0.02).
Smoking habit, AKI at diagnosis, ANA positivity and lumbar pain were associated with relapse of RF after initial remission due to steroid and/or TMX therapy; the combination of these conditions was also predictive of worse renal function outcome. Identification of risk factors for relapse can be useful not only to modulate the choice, the dosage of first-line treatment and the duration of maintenance therapy but also for preventing a progressive loss of kidney function, as well.
腹膜后纤维化(RF)是一种罕见的病因不明的疾病,其特征为腹膜后间隙存在纤维炎性组织,可包绕并阻塞腹膜后结构,尤其是输尿管。该病对类固醇治疗反应良好,但即使经过多年也容易复发。我们的研究目的是评估特发性腹膜后纤维化患者的长期肾脏预后,寻找疾病复发和进展为终末期肾病的预测风险因素。
对 2004 年至 2017 年期间诊断为特发性 RF 的患者进行回顾性观察性研究,并在类固醇首次疗程结束后至少随访 1 年,同时进行必要的输尿管处理。
本研究共纳入 43 例患者。中位随访时间为 93±52 个月。所有患者在治疗后均获得缓解,其中 26 例患者在最后一次观察时仍保持缓解。17 例患者至少复发 1 次。复发相关的风险因素包括吸烟史、起病时合并急性肾损伤(AKI)、腰痛和抗核抗体(ANA)阳性。在长期随访期间,肾功能保持相对稳定。8%的患者出现肾脏终点(血清肌酐加倍或终末期肾病);然而,复发患者的 eGFR 与诊断时非复发患者相似,但复发患者的 eGFR 随时间推移下降更明显(p 组=0.20;p 时间=0.001;p 时间×组交互作用=0.04)。根据这 4 个预测因素,患者被分为“低风险”(有 0-1 个风险因素)和“高风险”(有 3-4 个风险因素)。高风险患者的肾脏终点发生率为 40%,而低风险患者无一例发生(p=0.02)。
吸烟史、诊断时 AKI、ANA 阳性和腰痛与初始缓解后类固醇和/或他莫昔芬治疗后的 RF 复发相关;这些因素的组合也与更差的肾功能结局相关。复发风险因素的识别不仅有助于调整一线治疗的选择、剂量和维持治疗的持续时间,还可以预防肾功能的进行性丧失。